vanadium pentoxide has been researched along with Hyperplasia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barquet, A; Fortoul, TI; Gonzalez-Villalva, A; Martinez-Pedraza, M; Masso, F; Montano, LF; Mussali-Galante, P; Pinon-Zarate, G; Rodriguez-Lara, V; Rojas-Lemus, M | 1 |
| Billah, MM; Bond, R; Celly, CS; Chapman, RW; Deno, G; Fan, X; Fine, JS; Gonsiorek, W; Hey, JA; Hipkin, RW; Kung, TT; Minnicozzi, M; Phillips, JE; Rindgen, D | 1 |
2 other study(ies) available for vanadium pentoxide and Hyperplasia
| Article | Year |
|---|---|
Vanadium pentoxide inhalation provokes germinal center hyperplasia and suppressed humoral immune responses.
Topics: Air Pollutants; Animals; Antibody Formation; Antigens, CD19; Cardiovascular Diseases; Germinal Center; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hyperplasia; Immunization; Inhalation Exposure; Lymphocytes; Male; Megakaryocytes; Mice; Organ Size; Respiratory Tract Diseases; Spleen; Time Factors; Vanadium Compounds | 2008 |
A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.
Topics: Animals; Anti-Inflammatory Agents; Benzamides; Biological Availability; Bronchitis; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Bronchoscopy; Cell Line; Cell Membrane; Chemokines, CXC; Chemotaxis; Chemotaxis, Leukocyte; Cyclobutanes; Disease Models, Animal; Goblet Cells; Hyperplasia; Lipopolysaccharides; Lung; Macaca fascicularis; Male; Mice; Mice, Inbred BALB C; Mucins; Mucus; Neutrophils; Rats; Rats, Sprague-Dawley; Receptors, Interleukin-8A; Receptors, Interleukin-8B; Vanadium Compounds | 2007 |